Clinical Trial

Lenvatinib Plus DEB-TACE and HAIC vs. Lenvatinib Plus DEB-TACE for Large HCC With PVTT

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated January 29, 2025 (before its estimated July 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study is conducted to evaluate the efficacy and safety of lenvatinib plus transarterial chemoembolization (TACE) with drug-eluting beads (DEB-TACE) and hepatic artery infusion chemotherapy (HAIC) with FOLFOX regemen (Len+DEB-TACE+HAIC) versus lenvatinib plus DEB-TACE (Len+DEB-TACE) for large hepatocellular carcinoma (\> 7cm) with portal vein tumor thrombosis (PVTT).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-07-02.
Status change: Not Yet Recruiting → Recruiting 2025-01-26
Trial Details
NCT Number NCT06492395
Lead Sponsor Second Affiliated Hospital of Guangzhou Medical University
Conditions Hepatocellular Carcinoma Non-resectable
Enrollment 178 participants
Start Date 2024-08-01
Primary Completion 2026-07-31 (estimated)
Study Completion 2027-07-31 (estimated)
Updated on ClinicalTrials.gov 2025-01-29